Siona Eliyahu

TL;DR: A gene encoding a melanocyte lineage-specific protein (MART-1) that is a widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy is identified and opens possibilities for the development of immunotherapies for patients with melanoma.

TL;DR: Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.

TL;DR: One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis and appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.

TL;DR: The effects of plasmids encoding wild-type (wt) p53 on the ability of primary rat embryo fibroblasts to be transformed by a combination of mutant p53 and ras support the notions that wt p53 expression may be restrictive to neoplastic progression and that p53 inactivation may play a crucial role in tumorigenesis.

TL;DR: Four of ten HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag.